In 2023, Novo Nordisk (NVO) was the most valuable company in Europe due to the soaring demand for Ozempic and Wegovy, but, since then, the company has lost its grip on the anti-obesity market, Peter Loftus and Noemie Bisserbe of The Wall Street Journal reports. The company has lost market share due to production missteps and a bungled rollout of Wegovy that led to shortages. Meanwhile, Eli Lilly (LLY) has been proven to have the more effective weight-loss drug and a more promising pipeline for future treatments.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle
- Eli Lilly price target raised to $936 from $928 at Guggenheim
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
- Evernorth weight loss drug price point attractive compared to Hims, says Truist
- Citi says Evernorth plan ‘slight headwind’ to Hims & Hers
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue